Does Humana Cover Dupixent?
The verdict
Covered on most plans
Humana covers Dupixent on the specialty tier (Tier 4 on most 2025-2026 formularies) with prior authorization and indication-specific step therapy, dispensed through Humana's CenterWell preferred specialty pharmacy. Because Humana is predominantly a Medicare insurer, most members access Dupixent through Medicare Part D, where coinsurance is approximately 25-33% after the deductible and the $2,100 (2026) out-of-pocket cap provides critical cost protection. Per Sanofi/Regeneron, about 79% of Medicare Part D Dupixent recipients pay $0-$100 per month.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Humana using your member ID.
Key facts
Dupixent is placed on Tier 4 (specialty) on most Humana 2025-2026 formularies; CenterWell, Humana's specialty pharmacy, is the required dispensing pharmacy.
Humana — formulary and drug-coverage information
Approximately 79% of Medicare Part D Dupixent recipients pay $0-$100 per month under post-Inflation Reduction Act cost-sharing protections, according to Sanofi/Regeneron patient-access data.
Sanofi/Regeneron — Dupixent MyWay patient access data
The 2026 Medicare Part D out-of-pocket cap is $2,100; once a Humana Part D member reaches this threshold, they pay $0 for covered prescription drugs for the rest of the calendar year.
CMS.gov — Medicare Part D benefit parameters 2026
Medicare vs. commercial coverage
Whether Humana covers Dupixent depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D (Humana's primary business): Dupixent is on Tier 4 (specialty) on most Humana formularies with PA and indication-specific step therapy. Members pay approximately 25-33% coinsurance after the deductible; the $2,100 (2026) Part D out-of-pocket cap limits total annual drug spend — once reached, the plan covers 100% of covered drug costs for the rest of the year. Per Sanofi/Regeneron, about 79% of Medicare Part D Dupixent recipients pay $0-$100 per month under post-IRA catastrophic protections. Dispensing through CenterWell specialty pharmacy is required. The Dupixent MyWay copay card cannot be used by Medicare beneficiaries. When Dupixent is administered in a clinical setting, it can shift from Part D to Medicare Part B (medical benefit) — the benefit rail depends on the site of care.
Commercial / Employer
Group & marketplace plans
Commercial/Employer plans (Humana's limited commercial book): where Humana commercial plans exist, Dupixent is on the specialty tier with PA and indication-specific step therapy. The Dupixent MyWay copay card (Sanofi/Regeneron) can reduce out-of-pocket cost to as little as $0 for eligible commercially insured patients. ACA/Individual marketplace Humana plans (limited presence) cover Dupixent on the specialty tier with PA where offered. Medicaid: Humana-managed Medicaid covers Dupixent for approved indications per state PDL with PA and step therapy; nominal cost-share. Medical vs. pharmacy benefit note: Dupixent is primarily a self-injected pharmacy-benefit (Part D) drug; when clinic-administered, it can shift to the medical benefit under Part B or medical cost-share.
The 5 boxes you must tick to get approved
Commercial plans that will consider Dupixent require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Dupixent actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Approximately $3,993 per carton of 2 pre-filled pens (list price, Jan 2025 estimate); average retail approximately $5,350-$5,377 per month (estimate). Treat all cash figures as estimates — verify current pricing before use.
List price with no coverage — before any manufacturer savings card.
With coverage
Medicare Part D (operative for most Humana members): approximately 25-33% coinsurance after the deductible, capped at $2,100 for 2026. About 79% of Medicare Part D recipients on Dupixent pay $0-$100 per month per Sanofi/Regeneron. Commercial specialty tier: similar coinsurance range; Dupixent MyWay card as low as $0. Medicaid: nominal cost-share.
Typical monthly copay once prior authorization is approved.
Bridge program
Dupixent MyWay copay program (Sanofi/Regeneron): as little as $0 per month for eligible commercially insured patients. NOT available to Medicare, Medicaid, or other government-plan enrollees — this exclusion affects most Humana members, who are Medicare beneficiaries. Enroll at dupixent.com/myway or call 1-844-DUPIXENT.
Reduced copay through the assistance program, where eligible.
For Medicare members, the $2,100 (2026) Part D out-of-pocket cap is the most important cost protection — not the manufacturer card. All copay figures are estimates; confirm your exact cost-share on your Humana plan's Summary of Benefits or at Humana.com.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Search Dupixent on Humana's online drug-formulary tool
Go to humana.com and log in to access the drug-cost estimator or formulary search tool (or use the guest formulary lookup). Search for both 'Dupixent' and 'dupilumab.' Note the tier (typically Tier 4 specialty), the PA and step-therapy requirements, and that CenterWell is the required specialty pharmacy.
- 2
Have your specialist initiate a Prior Authorization
Your allergist, dermatologist, pulmonologist, or gastroenterologist submits the PA to Humana. Gather clinical documentation: diagnosis, prior treatment history demonstrating step-therapy completion, current disease severity, and supporting labs (eosinophil count for asthma). Humana's PA process is managed through its internal PBM. CenterWell coordinates dispensing once the PA is approved.
- 3
Understand the $2,100 Part D cap — especially critical for Humana Medicare members
Because most Humana members are Medicare beneficiaries, the $2,100 (2026) Part D out-of-pocket cap is the primary cost-control mechanism. Once you reach $2,100 in covered drug costs, you pay $0 for covered drugs for the remainder of the calendar year. If you need additional assistance before reaching the cap, ask your care team about Medicare Extra Help (Low Income Subsidy).
Options if Humana won't cover Dupixent
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Xolair (omalizumab), Nucala (mepolizumab), Tezspire (tezepelumab)
For asthma: Humana typically requires trials of one or more of these preferred asthma biologics before approving Dupixent. The required sequence is indication-specific; Xolair is the longest-established asthma biologic in the step-therapy chain.
Topical corticosteroids and calcineurin inhibitors
For atopic dermatitis: required step-therapy agents before Dupixent. Documented failure of high-potency topicals is a typical prerequisite for Humana PA approval.
Rinvoq (upadacitinib) — JAK inhibitor
Some Humana commercial plans require a JAK inhibitor trial for moderate-to-severe atopic dermatitis in adults before approving Dupixent. Check Humana's specific atopic dermatitis PA criteria. Note: JAK inhibitors carry an FDA boxed warning for serious risk; discuss with your prescriber.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Yes, Humana covers Dupixent on Tier 4 (specialty) on most 2025-2026 formularies with prior authorization and indication-specific step therapy, dispensed through CenterWell specialty pharmacy. Because Humana is predominantly a Medicare insurer, most members access Dupixent through Part D; the $2,100 (2026) out-of-pocket cap is the key protection. About 79% of Medicare Part D Dupixent recipients pay $0-$100 per month.
Step therapy requirements vary by indication. For atopic dermatitis, Humana typically requires documented failure of topical corticosteroids and often topical calcineurin inhibitors. For asthma, Humana generally requires trials of preferred biologics — Xolair, Tezspire, or Nucala — depending on phenotype. Your prescriber's PA submission must include clinical notes documenting these prior treatment steps.
Yes, CenterWell is Humana's preferred specialty pharmacy for Dupixent. After your PA is approved, CenterWell ships Dupixent directly to your home. Using an out-of-network specialty pharmacy under most Humana plans will result in higher cost-share or a denied claim. CenterWell also provides clinical pharmacist support and prior-authorization coordination assistance.
The 2026 Medicare Part D out-of-pocket cap is $2,100. Once a Medicare beneficiary (on a Humana Part D or Medicare Advantage plan) spends $2,100 on covered prescription drugs for the year, they pay $0 for covered drugs for the rest of that calendar year. For a drug like Dupixent, where coinsurance could otherwise run thousands of dollars annually, reaching this cap quickly and then paying nothing is the most important cost protection — and why about 79% of Medicare Part D recipients end up paying $0-$100 per month.
For most Humana members, Dupixent is covered under Medicare Part D (pharmacy benefit) when self-injected at home and dispensed by CenterWell. However, when Dupixent is administered by a clinician in an office or infusion setting, it can shift to Medicare Part B (medical benefit). The benefit rail — Part B vs Part D — depends on the site of care, not the drug itself. Verify the billing pathway with your prescribing specialist and Humana member services.
Related Articles
Does Aetna Cover Vyvanse? 2026 CVS Caremark Formulary
Aetna covers Vyvanse via CVS Caremark — generic lisdexamfetamine preferred, brand non-preferred. 70 mg/day QL per Policy 5.60.024; age-22 PA required.
Read moreDoes Aetna Cover Prolia? CVS Caremark Medical Benefit | Curex
Aetna covers Prolia under the medical benefit with PA — a q6-month clinic injection, not Part D. Jubbonti biosimilar now preferred on CVS Caremark.
Read moreDoes Anthem Cover Adderall? 2026 Coverage Guide | Curex
Anthem covers Adderall through CarelonRx — generic preferred, brand non-preferred. Step therapy may apply on some plans. Verify your Anthem plan.
Read moreDoes Anthem Cover Contrave? 2026 Brand Coverage Guide | Curex
Anthem covers Contrave only if your plan has a weight-loss benefit. Many plans carve it out. CurAccess ~$99/mo is often the fastest path.
Read moreDoes Aetna Cover Contrave? 2026 CVS Caremark Guide | Curex
Aetna (CVS Caremark) often excludes Contrave under AOM carve-outs. Where covered, CVS BMI prior auth applies. Medicare bars it by law. CurAccess ~$99/mo.
Read moreDoes Aetna Cover Forteo? 2026 Coverage Guide
Aetna (CVS) often excludes brand Forteo in favor of generic teriparatide or Bonsity. Teriparatide is covered with PA and bisphosphonate step therapy. 2026.
Read moreThis content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Humana before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.